Follow-up on health outcomes in patients with histiocytic disorders
Histiocytic Disorder Follow-up Study
This study looks at the long-term health effects of histiocytic disorders on around 6000 patients to see how these conditions impact their overall well-being and quality of life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 6000 (estimated) |
| Ages | 0 Years to 89 Years |
| Sex | All |
| Sponsor | University of Alabama at Birmingham Academic / other |
| Locations | 1 site (Birmingham, Alabama) |
| Trial ID | NCT05915208 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the long-term health impacts of histiocytic disorders, including chronic health conditions, psychological issues, and overall quality of life. By utilizing a retrospective cohort design, the study will gather data from approximately 6000 patients diagnosed with various histiocytic disorders through validated questionnaires. The focus is on understanding the burden of morbidity and mortality associated with these conditions, particularly in relation to healthcare utilization and the risk of secondary malignancies.
Who should consider this trial
Good fit: Ideal candidates for this study are individuals of any age diagnosed with a histiocytic disorder such as Langerhans cell histiocytosis or Erdheim-Chester disease.
Not a fit: Patients without a diagnosis of a histiocytic disorder will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved follow-up guidelines and better management strategies for patients with histiocytic disorders.
How similar studies have performed: While there have been institutional studies on pediatric LCH, this study aims to fill a gap in understanding the broader implications of histiocytic disorders in both pediatric and adult populations.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * diagnosis of histiocytic disorder at any age 1. Langerhans cell histiocytosis, 2. Erdheim-Chester disease, 3. Rosai-Dorfman disease, 4. Xanthogranuloma, 5. Mixed histiocytosis 6. Malignant histiocytosis (Histiocytic sarcoma, langerhans cell sarcoma, interdigitating cell sarcoma) 7. Hemophagocytic lymphohistiocytosis Exclusion Criteria: * None
Where this trial is running
Birmingham, Alabama
- University of Alabama at Birmingham — Birmingham, Alabama, United States (Recruiting)
Study contacts
- Principal investigator: Gaurav Goyal, MD — University of Alabama at Birmingham
- Study coordinator: Gaurav Goyal, MD
- Email: histio@uabmc.edu
- Phone: 1-866-438-1640
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.